Global Gastritis Market – Industry Trends and Forecast to 2029

Gastritis Market Analysis and Size

The gastritis market is expected to witness significant growth during the forecast period. The gastritis treatment market is projected to exhibit a healthy growth rate during the forecast period. There are numerous causes of gastritis but one of the most common causes is Helicobacter pylori, a bacterium that infects the stomach lining. If left untreated, gastritis caused by Helicobacter pylori can lead to ulcers and stomach cancer. Enlarged alcohol abuse and major market players are projected to boost the market forward. As per a published poll, nearly one in every 100 people in the U.S. suffers from gastritis.

Data Bridge Market Research analyses a growth rate in the global gastritis market in the forecast period 2022-2029. The expected CAGR of gastritis market is tend to be around 4% in the mentioned forecast period. The market was valued at USD 162.2 million in 2021, and it would grow upto USD 221.98 million by 2029. In addition to the market insights such as market value, growth rate, market segments, geographical coverage, market players, and market scenario, the market report curated by the Data Bridge Market Research team also includes in-depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.

Gastritis Market Scope and Segmentation

Market Definition

Gastritis is the irritation, inflammation, or erosion of the stomach lining. It may be acute or chronic. The patient shows some symptoms or no symptoms at all. Typically, the symptoms include upper abdominal pain, nausea, and vomiting. Gastritis may lead to stomach tumors, bleeding, and stomach ulcers. Gastritis is generally caused by the bacteria helicobacter pylori or by the use of nonsteroidal anti-inflammatory drugs or NSAIDs. This disease prevalence is rising and important diagnostic procedures and treatments will boost the growth of the market.

Global Gastritis Market Dynamics

Drivers

• Increased Gastrointestinal Disorders

As per the records of the Centers for Disease Control and Prevention (CDC), it is projected that around 1-1.3 million people are suffering from Inflammatory Bowel Disease (IBD) in U.S. Incidence of Crohn’s disease and ulcerative colitis is 201 per 100,000 adults and 238 per 100,000 adults, respectively. thus boosting the market growth.

• Higher Rate of Drug Approvals and Launches       

An extensive range of new-generation therapeutics targets, including novel small molecules and cellular therapy, are currently under process. These include mongersen, tofacitinib, ustekinumab, and vedolizumab. This influx is expected to be a consequence of rising prevalence of gastrointestinal diseases worldwide. In addition to this, Vedolizumab is developing as a first-line biologic therapy for Crohn’s disease. Currently, the U.S. FDA has approved Humira, Amjevita, Remicade, Renflexis, Cimzia, Inflectra, Tysabri, and Entyvio for the treatment of Crohn’s disease. Thus, all these developments are boosting the growth of the market.

Opportunities

• High-end Efficiency of Biologics

Some studies have specified that biologics show greater long-term efficiency. According to a study which University of Chicago conducted, it was witnessed that the usage of biologics has resulted in a complete reduction in the number of surgeries by around 40.0%, emergency room visits by 60.0%, and hospitalizations by 50.0%. All these factors are also contributing in the growth of the market.

Restraints/Challenges

• Higher Expenditure Associated With Gastritis Treatment

High-end expenditures regarding the drug manufacturing and development process are hampering the market's growth. High initial investment required in the R&D activities for developing vaccines, drugs, and kits used in the treatment are restraining growth of the gastritis treatment market.

• Unavailability of Appropriate Treatments

To treat conditions which are rare, many a times all treatments are not available, especially in the under-developed countries. The severe patients needs to be treated with advanced techniques but at times, these are not available in the hospitals and clinics. Thus, it hampers the market growth.

This global gastritis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the global gastritis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

COVID-19 Impact on Global Gastritis Market

 During the pandemic, it has been witnessed that gastrointestinal disorders are greatly associated with COVID-19 patients. The severity of COVID-19 is combined with a set of comorbidities such as diabetes, obesity, hypertension, and/or advanced age that seriously aggravates the consequences of the infection. Additionally, gastrointestinal symptoms, such as vomiting, diarrhea, or abdominal pain during the early phases of COVID-19 are also witnessed. Thus, diagnosing gastrointestinal symptoms that lead respiratory problems during COVID-19 became necessary for early detection and treatment. Thus, COVID-19 left a major impact on global gastritis market.

Global Gastritis Market Scope

The global gastritis market is segmented on the basis of treatment, route of administration, end-user, distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Treatment

• Acid Blocking Medications
• Prevacid 24HR (lansoprazole)
• Nexium 24HR
• Acid Reducing Medications
• Nexium
• Prevacid
• Antacids
• Aluminium hydroxide
• Magnesium carbonate
• Antibiotics
• Amoxicillin
• Doxycycline
• Others

Type

• Acute Gastritis
• Chronic Gastritis
• Erosive Gastritis
• Non-Erosive Gastritis

Route of Administration

• Oral
• Parenteral

End-Users

• Hospitals
• Homecare
• Specialty Clinics
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacies
• Others

Gastritis Market Regional Analysis/Insights

The global gastritis market is analyzed and market size insights and trends are provided by treatment, route of administration,end-user, distribution channel as referenced above.

The major countries covered in the global gastritis market report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is considered to have the highest lucrative growth in the forecast period to the increase prevalence of gastritis, vulnerable unhealthy lifestyles of the population and advanced healthcare facilities.

Asia-Pacific is dominating the market due to the increase’s cases of gastritis and rapidly aging population.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Global Gastritis Market Share Analysis

The global gastritis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to global gastritis market.

Key players operating in the global gastritis market include:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Israel)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GSK plc (U.K.)
• Novartis AG (Switzerland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (U.S.)
• Sun Pharmaceutical Industries Ltd. (India)
• Merck & Co., Inc. (U.S.)
• Lilly (U.S.)
• Amgen Inc. (U.S.)
• Dr. Reddy's Laboratories Ltd (India)
• Endo International plc (Ireland)
• Lupin (India)
• Zydus Group (India)

SKU-54485